Rubicatin Indian generic drug

Lurbinectedin, also known asLurbinectedin, is an innovative drug for the treatment of metastatic small cell lung cancer after platinum-based chemotherapy, especially for adult patients with disease progression.

It is administered by intravenous infusion, and every 21 days is a treatment cycle. The recommended dose is 3.2mg/m², and the infusion time must exceed 60 minutes. The unique mechanism of Rubicatin is that it can bind to DNA, interfere with the replication of tumor cells, and thereby inhibit the growth and spread of lung cancer cells.

In addition, it can destroy existing blood vessels and effectively inhibit the development and metastasis of lung cancer. However, when using rubicatin, it is necessary to pay attention to the patient's blood cell count to ensure that the number of neutrophils and platelets reaches a certain standard before starting treatment.

Although medications may cause side effects such as nausea and vomiting, they are usually controllable and strategies are available to deal with them. Overall, rubicatin offers new therapeutic hope for lung cancer patients, especially those whose disease has progressed despite platinum-based chemotherapy. Its remarkable efficacy and unique mechanism of action play an important role in the field of lung cancer treatment.

Currently, Rubicatin has not yet been launched in the Chinese market, and there are currently no related imitation versions available overseas. For patients in need, you can consider purchasing through foreign channels, or contact a reputable overseas medical consulting company for assistance. Currently, the only original version of Rubicatin available on the market is produced by the Spanish biopharmaceutical company PharmaMar. This version is sold in both Singapore and the United States. The specification is 4 mg. The price in the United States is 91,000 yuan per box, while in Singapore it is only 34,000 yuan per box.